Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and the published bioaccess® Brazil country page. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANVISA, CEP, and FDA rules with qualified advisers. We name only the facility string and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Universidade Federal de Pernambuco as a bioaccess® client.
If you searched Universidade Federal de Pernambuco first-in-human, UFPE clinical trials, Federal University of Pernambuco CRO, or “go direct UFPE Recife,” you followed a campus string ClinicalTrials.gov still publishes. Universidade Federal de Pernambuco in Recife is a real federal university. It is not a first-in-human medical-device CRO, and it is not the operator of the ANVISA file.
bioaccess®’s position is simple and it is not adversarial: the campus is the site. The First-in-Human CRO still owns ANVISA/CEP, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if Recife is not the only fit. Sponsors who skip the CRO and email the university still have to rebuild that stack. An NCT location row is not a CRO.
This page is the intercept for the NCT campus string Universidade Federal de Pernambuco. It does not clone São Paulo intercepts already live (InCor, Dante Pazzanese) or the Porto Alegre pages. Recife is a different city.
Why the campus name wins the search — and why that is not a CRO
On the 1 September 2026 ClinicalTrials.gov LATAM DEVICE sweep, Universidade Federal de Pernambuco, Recife, Brazil, is rank 8, n=12, sponsor class OTHER:12 on that ranking row. Example NCT IDs: NCT01449643, NCT01932684, NCT02600052.
Public snapshots of those three IDs list lead sponsor Universidade Federal de Pernambuco. Brief titles concern inspiratory muscle training and diaphragmatic mobility, incentive spirometry / breath stacking in Parkinson’s disease, and proprioceptive neuromuscular facilitation breathing plus aerobic training. We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this university as a client site. Ranking n=12 is registry volume, not a CRO product.
That is the leak: a founder searching “UFPE device trial” or “Recife first-in-human” finds a federal campus without finding ANVISA, import, insurance, or 21 CFR 812.28.
The site is the site. The CRO is the operator.
A Recife federal university can provide labs, coordinators, institutional CEP calendars, and investigators who have already appeared on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the university can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing department.
- Share institutional CEP calendars and university research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the university is not built to own for an investigational device:
- ANVISA. Device investigations sit under RDC 837/2023 (dossier in Portuguese: IB, protocol, ICF, insurance, GMP evidence). A Recife hallway conversation is not that dossier.
- CEP. Institutional ethics under Law 14874. The CEP is tied to the host institution once the site is chosen.
- Investigational import into Brazil is a separate permit from trial authorization and from later market registration. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a Recife-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF.
- The 21 CFR 812.28 package. Eligibility is not clearance. A site MSA does not produce it.
- Multi-country optionality. If Recife enrollment or the indication later needs São Paulo, Porto Alegre, Bogotá, or Panama City, a single-campus MSA will not stretch.
Going direct to Universidade Federal de Pernambuco is how you confirm a room. It is not how you open an investigational file.
Site versus CRO
| Workstream | What UFPE (site) typically owns | What the CRO still owns |
|---|---|---|
| Procedure | Labs, rooms, local staff, source documents | Protocol fit, training, device accountability |
| Ethics | Institutional CEP calendar and local rules | Packet, ICF, IB alignment, deficiency cycle |
| National authority | Not the permit holder by appearing on an NCT | ANVISA clinical-investigation dossier (RDC 837/2023) |
| Import | Receiving and storage if contracted | Importer of record |
| Quality | University quality and the case | ISO 14155 monitoring, EDC, SAE, TMF |
| FDA conversation | Source documents from cases they run | 21 CFR 812.28 narrative — eligibility, not clearance |
| Country optionality | One Recife campus | Colombia (INVIMA) and the rest of the bioaccess® platform |
How ANVISA and CEP actually work (the short version)
Use clinical-trials-brazil for the full pathway. Facts a sponsor searching this campus needs on one screen, already published there and not re-averaged here:
- Combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023.
- Ethics committees (CEPs) are capped at 30 business days. The CEP is tied to the host institution once the site is chosen — which is why “we already have this campus” still leaves the packet to write.
- Published per-patient range $20,000–$35,000; 15+ pre-qualified sites; ANVISA is a WHO-listed authority.
- For early feasibility studies not intended for Brazilian market clearance, only institutional CEP approval is required — no CONEP review for most investigations under Law 14874.
- Trial authorization and later ANVISA market registration (RDC 751/2022 / BRH) are separate workstreams.
- Under 21 CFR 812.28, foreign clinical data from Brazil is eligible for FDA submission and review when studies are conducted under ISO 14155 with proper ANVISA authorization and CEP ethics approval. Eligibility is not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Ask for a protocol-specific calendar. A hospital or university email is not an ANVISA approval. bioaccess® manages the dossier in Portuguese. That is CRO work, not site work.
All bioaccess® Brazil device protocols are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval.
Do not smear the university
Universidade Federal de Pernambuco is a serious academic resource. Ranking eighth on a public DEVICE facility list is a signal of registry volume, not a punchline. This page is not a critique of physiotherapy or respiratory-device listings on ClinicalTrials.gov. Volume is still not a device-CRO quality system. Use the site when the protocol fits. Hire the operator. Do not merge Recife into InCor, Dante Pazzanese, or Hospital de Clínicas de Porto Alegre.
What the CRO still does after you have a UFPE slide
- Regulatory-fit, not tourism. Brazil is a sourced device geography. Recife is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the ANVISA/CEP packet.
- Importer of record and device accountability.
- Site activation that is more than a tour. Activate UFPE only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative for a later FDA conversation — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract Universidade Federal de Pernambuco directly for a device FIH?
You can try. The university can discuss investigator interest, local visit costs, and CEP calendars. It cannot, by ranking n=12 on the DEVICE sweep, become your ANVISA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run NCT01449643, NCT01932684, or NCT02600052?
No public bioaccess® case-study page says so. We will not invent that claim. This page intercepts the search; it does not claim the studies.
If I already have Recife, what does the CRO still do?
Regulatory-fit (Brazil vs Colombia vs a multi-site Brazil design); the ANVISA/CEP packet; insurance; import; contracts and activation; ISO 14155 and the 812.28 narrative; optionality if one Recife room is not enough.
Next step
If the search that brought you here was Universidade Federal de Pernambuco or UFPE, start as the operator: contact bioaccess® or book from First-in-Human CRO. Country: clinical trials in Brazil.
Julio G. Martinez-Clark, CEO · bioaccess®